Protocol No.: ALXN1720-MG-301

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis Protocol Number: ALXN1720-MG-301 IND Number: 150823
Principal Investigator
Sultan, Shumaila
Phase
III
Age Group
Adult
Applicable Disease Site
Neurology
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Lauren Chase, RN
Clinical Research Specialist
Phone: +1 304-598-4000

View on ClinicalTrials.gov